Engineered immune cells take on Hard-to-Treat cancers
NCT ID NCT07644403
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new treatment called IMC001 for people with advanced epithelial solid tumors (cancers that start in the lining of organs). IMC001 is made from a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial has two parts: first, finding a safe dose, then testing how well it works in about 30 patients. The main goals are to check safety and see if tumors shrink.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- IMC001 (a CAR-T cell therapy targeting EpCAM)
- What this could lead to
- If successful, this could point toward a new treatment option for advanced epithelial cancers that are hard to treat.
- What could go wrong
- This is an early, small trial (30 people) focused on safety and dosing. Many early-stage therapies fail to show enough benefit or have serious side effects like cytokine release syndrome.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL CANCER PATIENTS are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing Cancer Hospital
Beijing, China